Ten years on, PMSMA continues to shape safer motherhood in India

7.5 crore antenatal check-ups and 1.2 crore high-risk pregnancies identified under flagship programme as maternal and neonatal mortality declines

Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment

These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients

Glenmark's interim data from PMS Study on Favipiravir released

The study was conducted in patients with mild to moderate COVID-19

Dr Jitendra Singh commends SCTIMST doctors for treating 17,000 patients under AB-PMJAY

At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology

Roche BTK drug emerges as potential breakthrough in primary progressive MS

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education

FDA setback for Sanofi’s Tolebrutinib in progressive MS

Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity

Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis